Facebook
Twitter
LinkedIn
Forward
Organic Psychosis Causing Secondary Schizophrenia in One-Fourth of a Cohort of 200 Patients Previously Diagnosed With Primary Schizophrenia
Instructions
Click the red REGISTER button to pay the $10 fee and take the posttest.
Click here to return to the PCC CME article.
Overview
Patients with psychosis are too often diagnosed with primary schizophrenia when the psychotic symptoms may actually be the manifestation of neurologic, endocrine, or immunologic disease. Learn about alternate diagnoses in this CME journal article.
Read the whole article at psychiatrist.com here:
Organic Psychosis Causing Secondary Schizophrenia in One-Fourth of a Cohort of 200 Patients Previously Diagnosed With Primary Schizophrenia
© Copyright 2020 Physicians Postgraduate Press, Inc.
Target Audience
Primary care clinicians
Learning Objectives
Provide complete assessment of patients with psychosis to better distinguish between primary schizophrenia and other diagnoses
CME Background
Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.
CME Objective
After studying this article, you should be able to:
- Provide complete assessment of patients with psychosis to better distinguish between primary schizophrenia and other diagnoses
Statement of Need and Purpose
Organic psychosis may cause secondary schizophrenia, which unfortunately is underestimated by clinicians. Many patients are wrongly diagnosed with primary schizophrenia. Clinicians have reported assigning the diagnosis of schizophrenia to patients even when this decision was controversial among their colleagues, believing that having a diagnosis would help the patient, even if it was incorrect, because treatment could begin. An educational intervention for clinicians is needed to improve recognition of causes of secondary schizophrenia and to increase provision of appropriate treatment.
Release, Expiration, and Review Dates
This educational activity was published in March 2020 and is eligible for AMA PRA Category 1 Credit™ through April 30, 2022. The latest review of this material was March 2020.
Disclosure of off-label usage
The author has determined that, to the best of his knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this article.
Funding/support
None.
Faculty Affiliation
João Gama Marques, MD*
Consulta de Esquizofrenia Resistente, Hospital Júlio de Matos, Centro Hospitalar Psiquiátrico de Lisboa, Lisbon, Portugal, and Clínica Universitária de Psiquiatria e Psicologia Médica, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
*Corresponding author: João Gama Marques, MD, Hospital Júlio de Matos, Avenida do Brasil, 53, Lisbon 1749-002, Portugal ([email protected]).
Financial Disclosure
All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Larry Culpepper, MD, MPH, Editor in Chief of The Primary Care Companion for CNS Disorders, has been a consultant for Acadia, Allergan, Eisai, Merck, Supernus, and Takeda; has been a stock shareholder of M-3 Information; and has received royalties from UpToDate and Oxford University Press. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosure appears at the end of the article.
Dr Gama Marques has no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation